SanofiSNYNASDAQ
Loading
R&D Expense Growth AcceleratingAccelerating
Percentile Rank100
3Y CAGR+70.7%
5Y CAGR+10.9%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
+70.7%/yr
Quarterly compound
5Y CAGR
+10.9%/yr
Recent acceleration
Percentile
P100
Near historical high
vs 5Y Ago
1.7x
Solid growth
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 24.92% |
| Q3 2025 | -3.93% |
| Q2 2025 | 5.59% |
| Q1 2025 | -14.68% |
| Q4 2024 | 14.42% |
| Q3 2024 | 8.69% |
| Q2 2024 | 2.04% |
| Q1 2024 | -10.79% |
| Q4 2023 | 12.57% |
| Q3 2023 | 2.02% |
| Q2 2023 | 4.29% |
| Q1 2023 | -14.26% |
| Q4 2022 | 5.01% |
| Q3 2022 | 4.70% |
| Q2 2022 | 11.35% |
| Q1 2022 | -6.12% |
| Q4 2021 | 9.83% |
| Q3 2021 | 3.36% |
| Q2 2021 | 10.35% |
| Q1 2021 | -16.55% |
| Q4 2020 | 14.84% |
| Q3 2020 | -2.29% |
| Q2 2020 | 0.90% |
| Q1 2020 | -20.52% |
| Q4 2019 | 23.97% |
| Q3 2019 | -14.30% |
| Q2 2019 | 14.58% |
| Q1 2019 | -17.46% |
| Q4 2018 | 14.85% |
| Q3 2018 | -0.95% |
| Q2 2018 | 15.23% |
| Q1 2018 | -12.57% |
| Q4 2017 | 9.17% |
| Q3 2017 | -1.25% |
| Q2 2017 | 3.74% |
| Q1 2017 | -8.91% |
| Q4 2016 | 17.69% |
| Q3 2016 | -4.53% |
| Q2 2016 | 3.56% |
| Q1 2016 | -0.24% |